Scoop has an Ethical Paywall
Work smarter with a Pro licence Learn More

News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Tennis elbow clinical trial at Dunedin School of Medicine

Tennis elbow clinical trial at the Dunedin School of Medicine, patients and funding wanted


(PR.co.nz) Globally, 3% of the population suffers from a Tennis Elbow (lateral epicondylitis) inflammation. A highly successful experimental device has been recently tested in Germany using a very densed acoustic pressure which loosens both inflammation and scar tissue in only 24 hours.


An exclusive clinical trial will be conducted at the Dunedin School of Medicine. For this clinical trial we need both patients who have suffered more than 12 months as well as funding.


We believe this technology can also be applied to other inflammation related conditions such as golfers arm, lower back pain, ballet injuries and even tendon injuries in horses.


Musculoskeletal conditions account for the third leading cause of health systems expenditure in Australia. Lateral epicondylalgia (tennis elbow) is such a condition and is often treated in primary care. Both the individual and community are affected by this condition: 7 per 1000 patients seeing their medical doctor have this condition. Most are not tennis related. On average 10-30% of sufferers take 12 weeks off work. The condition may last 6-48 months and it tends to become stubborn to treatment and recurs often.


ends

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.